• 2-May-2016: USPTO inter partes review of Teva’s three Orange Book patents for the 40mg formulation of Copaxone. (Approximately 80% of patents where the USPTO grants an IPR are ultimately invalidated; if Teva’s 40mg Copaxone patents are invalidated, MNTA could launch a generic version of 40mg Copaxone, with FDA approval, as soon as Jan 2017, when Teva’s Hatch-Waxman exclusivity on the 40mg formulation expires.)
• 26-Sep-2016: US patent trial on Teva’s 40mg Copaxone patents. (This trial may be mooted if the May 2016 IPR [above] invalidates Teva’s patents.)
Lovenox program
• 2016: US District Court trial of NVS/MNTA vs AMPH/AGN on infringement of MNTA’s Lovenox patents, which could result in substantial damages payable to NVS/MNTA. (The Appellate Court remanded the case to the District Court on 11/10/15, finding that AMPH/AGN are not protected by the Hatch-Waxman Safe Harbor: #msg-118404904, #msg-115468100.)
FoB program
• Before end 2015: Partnership deal for MNTA’s FoB compounds other than Humira. (MNTA’s Humira FoB is already partnered with BXLT.)
• Jan 2016: USPTO inter partes review against BMY on US Orencia patent.
• Early 2016: PK/PD data for Humira FoB. (The phase-3 trial in psoriasis started on 10/5/15; regulatory submissions expected in 2017 if no hitch.)
• 2H16: Orencia FoB starts phase-1.
• Timing unknown: New pipeline disclosures re M597, M615, M282, M706, M730, or M740. (See slide #53 at link in #msg-107107809.)
Sialylated IVIG program
• Late 2016: Start phase-1 trials for first two of three sialylated-IVIG candidates (of which two are recombinant and one is plasma-derived). The third candidate will start phase-1 in 2017.
Market Data 
Markets 
AI
